NASDAQ$IRMD
IRadimed Corporation · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
IRadimed reported record revenue for the sixth consecutive quarter and approved a special cash dividend.
IRadimed Corporation announced its Q4 and full year 2022 financial results, reporting a revenue of $14.9 million for the quarter and $53.3 million for the year. The Board of Directors approved a special cash dividend of $1.05 per share. The company ended the year with $57.9 million in cash and cash equivalents and no debt.
- Reported fourth quarter revenue of $14.9 million, GAAP diluted EPS of $0.29 and non-GAAP diluted EPS of $0.32.
- Reported full-year revenue of $53.3 million, GAAP diluted EPS of $1.02 and non-GAAP diluted EPS of $1.10.
- Board of Directors approved a special cash dividend of $1.05 per share.
- Ended the year with $57.9 million in cash and cash equivalents and no debt.
Headline financials
Revenue & EPS history
IRadimed · Revenue · Quarterly
$14.9M
Forward guidance
For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34. For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.
Tailwinds
- Revenue of $61 million to $63 million
- GAAP diluted earnings per share of $1.10 to $1.20
- Non-GAAP diluted earnings per share of $1.23 to $1.34
- First quarter revenue of $14.6 million to $14.9 million
- First quarter GAAP diluted earnings per share of $0.23 to $0.25
Headwinds
- Stock-based compensation expense impacts non-GAAP diluted earnings per share guidance
- Potential disruptions in our limited supply chain for our products
- The Company's ability to receive FDA 510(k) clearance for new products and product candidates
- Unexpected costs, delays or diversion of management's attention associated with the design, manufacture or sale of new products
- The Company's ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+2.2%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.8%
Avg return
30 days after
59%
30 / 51 earnings
Positive
+32.1%
Q2 2019
Best reaction
-20.0%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | +3.4% | +8.6% | |
| Q4 2025 | +9.6% | +4.0% | +3.5% | |
| Q3 2025 | +9.4% | +9.8% | +21.3% | |
| Q1 2025 | -2.3% | -3.0% | +13.7% | |
| Q4 2024 | -8.4% | -5.8% | -13.3% | |
| Q3 2024 | -8.8% | -0.4% | +1.9% | |
| Q2 2024 | -4.9% | -6.6% | +0.5% | |
| Q1 2024 | +6.4% | +4.0% | +1.1% | |
| Q4 2023 | -6.9% | -3.3% | -5.2% | |
| Q3 2023 | +3.5% | -1.3% | +3.5% | |
| Q2 2023 | +10.7% | +10.4% | +9.7% | |
| Q1 2023 | +8.5% | +8.3% | +13.0% | |
| Q4 2022 | +10.1% | -0.3% | +3.7% | |
| Q3 2022 | +5.2% | +6.0% | +9.4% | |
| Q2 2022 | -1.4% | -3.2% | -17.8% | |
| Q1 2022 | -17.2% | -21.5% | -19.4% | |
| Q4 2021 | +19.8% | +33.5% | +24.1% | |
| Q3 2021 | +6.4% | +5.1% | +16.8% | |
| Q2 2021 | +1.0% | -1.8% | -2.2% | |
| Q1 2021 | +5.9% | +9.2% | +3.9% | |
| Q4 2020 | -7.2% | -2.4% | -7.8% | |
| Q3 2020 | +3.1% | +2.7% | +9.0% | |
| Q2 2020 | -4.2% | -2.7% | -7.2% | |
| Q1 2020 | -7.9% | -8.4% | +8.1% | |
| Q4 2019 | +2.4% | -0.5% | -10.8% | |
| Q3 2019 | +5.5% | +1.9% | -8.2% | |
| Q2 2019 | +32.1% | +23.6% | +7.1% | |
| Q1 2019 | -20.0% | -15.1% | -25.3% | |
| Q4 2018 | -0.4% | -0.9% | -12.4% | |
| Q3 2018 | +1.7% | +4.8% | +16.1% | |
| Q2 2018 | +4.6% | +9.8% | +17.5% | |
| Q1 2018 | +13.6% | +15.1% | +17.0% | |
| Q4 2017 | -6.3% | -7.3% | -13.6% | |
| Q3 2017 | +12.2% | +7.1% | +11.0% | |
| Q2 2017 | +17.3% | +14.9% | +18.5% | |
| Q1 2017 | -3.4% | -3.4% | -6.2% | |
| Q4 2016 | -4.0% | -2.8% | -2.8% | |
| Q3 2016 | +2.2% | +0.5% | +22.7% | |
| Q2 2016 | +2.8% | -4.6% | -1.2% | |
| Q1 2016 | -5.6% | — | — | |
| Q4 2015 | -17.1% | — | — | |
| Q3 2015 | +11.6% | — | — | |
| Q1 2014 | +0.2% | — | — | |
| Q2 2015 | +18.6% | — | — | |
| Q1 2015 | +2.2% | — | — | |
| Q4 2014 | +7.2% | — | — | |
| Q3 2013 | +4.9% | — | — | |
| Q3 2014 | +4.9% | — | — | |
| Q4 2013 | -2.3% | — | — | |
| Q2 2013 | -2.3% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro